Indication
For treatment of adult patients with active radiographic axial spondyloarthritis (rad-axSpA; also known as ankylosing spondylitis [AS] in the literature) who have responded inadequately to conventional therapy and adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).
Medicine details
- Medicine name:
- ixekizumab (Taltz)
- SMC ID:
- SMC2440
- Pharmaceutical company
- Eli Lilly and Company Ltd
- BNF chapter
- Musculoskeletal and joint diseases
- Submission type
- Full
- Publication due date:
- 13 June 2022
- SMC meeting date:
- 03 May 2022
- Patient group submission deadline:
- 04 April 2022